Log in to your Inderes Free account to see all free content on this page.
Xspray Pharma
80.1 SEK -6.43%2 investors are following this company
Xspray Pharma is a pharmaceutical company with the goal of improving the quality of life for cancer patients. The company has several product candidates in the clinical development phase and plans to launch its first product on the US market during september 2024. Based on a patented technology for the amorphous formulation of drugs, the company develops product candidates with relevant medical benefits that should be able to be marketed as improved versions of established drugs for the treatment of cancer (protein kinase inhibitors, PKIs).
Read moreRevenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
XSPRAY
Daily low / high price
78.9 / 88.8
SEK
Market cap
2.7B SEK
Turnover
11.8M SEK
Volume
143K
Financial calendar
Interim report
07.08.2024
Interim report
06.11.2024
Annual report
12.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 17.2 % | 17.2 % |
Ribbskottet | 12.6 % | 12.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
New number of shares and votes in Xspray Pharma after TO6
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio